In recent years, triple-negative breast cancer (TNBC) has emerged as the most 
aggressive subtype of breast cancer and is usually associated with increased 
mortality worldwide. The severity of TNBC is primarily observed in younger 
women, with cases ranging from approximately 12%-24% of all breast cancer cases. 
The existing hormonal therapies offer limited clinical solutions in completely 
circumventing the TNBC, with chemoresistance and tumor recurrences being the 
common hurdles in the path of TNBC treatment. Accumulating evidence has 
correlated the dysregulation of long noncoding RNAs (lncRNAs) with increased 
cell proliferation, invasion, migration, tumor growth, chemoresistance, and 
decreased apoptosis in TNBC. Various clinical studies have revealed that 
aberrant expression of lncRNAs in TNBC tissues is associated with poor 
prognosis, lower overall survival, and disease-free survival. Due to these 
specific characteristics, lncRNAs have emerged as novel diagnostic and 
prognostic biomarkers for TNBC treatment. However, the underlying mechanism 
through which lncRNAs perform their actions remains unclear, and extensive 
research is being carried out to reveal it. Therefore, understanding of 
mechanisms regulating the modulation of lncRNAs will be a substantial 
breakthrough in effective treatment therapies for TNBC. This review highlights 
the association of several lncRNAs in TNBC progression and treatment, along with 
their possible functions and mechanisms.